<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339999</url>
  </required_header>
  <id_info>
    <org_study_id>1957-201-001</org_study_id>
    <nct_id>NCT03339999</nct_id>
  </id_info>
  <brief_title>AGN-242428 in the Treatment of Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitae Pharmaceuticals Inc., an Allergan affiliate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitae Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics
      and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe
      plaque-type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    safety reason
  </why_stopped>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of participants achieving a reduction (improvement) in Psoriasis Area and Severity Index (PASI) score of ≥ 75% from baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The PASI score ranges from 0-72 (with a higher score indicating greater severity of psoriasis), based on a combination of the severity (erythema, induration, and desquamation) of psoriasis and percentage of affected area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving ≥ 2-point improvement in Physician's Global Assessment (PGA) score at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The investigator evaluates the participant's overall severity of psoriasis using a 5-point scale (0 to 4) where 0=Clear and 4=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a clear (0) or almost clear (1) score in PGA at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The investigator evaluates the participant's overall severity of psoriasis using a 5-point scale (0 to 4) where 0=Clear and 4=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a reduction of 50% from baseline in PASI score at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The PASI score ranges from 0-72 (with a higher score indicating greater severity of psoriasis), based on a combination of the severity (erythema, induration, and desquamation) of psoriasis and percentage of affected area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving a reduction of 90% from baseline in PASI score at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The PASI score ranges from 0-72 (with a higher score indicating greater severity of psoriasis), based on a combination of the severity (erythema, induration, and desquamation) of psoriasis and percentage of affected area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with a clinically relevant change from baseline in electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to Week 18 plus 3 days</time_frame>
    <description>Standard 12-lead ECGs will be performed at each scheduled visit throughout study. Follow-up visit occurs up to 17 days after after completion or premature discontinuation of study medication. While the last dose of study medication is given at Week 16, there will be an additional visit (Week 18), no later than 17 days after Week 16, where participant ECG values are recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AGN-242428 at Early Termination</measure>
    <time_frame>Early Termination (From Day 1 until Week 16)</time_frame>
    <description>Blood samples for the analysis of AGN-242428 plasma concentrations will be collected at the early termination visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experienced an Adverse Event (AE)</measure>
    <time_frame>From Consent (Week -4) up to Week 18 plus 30 Days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. While the last dose of study medication is given at Week 16, there will be an additional visit (Week 18), no later than 17 days after Week 16, where participant adverse events are recorded. Adverse events are recorded for an additional 30 days after visit 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experienced an Adverse Event related to study treatment</measure>
    <time_frame>Baseline up to Week 18 plus 30 Days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. While the last dose of study medication is given at Week 16, there will be an additional visit (Week 18), no later than 17 days after Week 16, where participant adverse events are recorded. Adverse events are recorded for an additional 30 days after visit 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experienced an Adverse Event (AE) leading to discontinuation</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. While the last dose of study medication is given at Week 16, there will be an additional visit (Week 18), no later than 17 days after Week 16.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>AGN-242428 Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-242428 and placebo, oral administration, once-daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242428 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-242428, oral administration, once-daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-242428 Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-242428, oral administration, once-daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral administration, once-daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-242428</intervention_name>
    <description>AGN-242428 administered as an oral capsule(s) once daily</description>
    <arm_group_label>AGN-242428 Lower Dose</arm_group_label>
    <arm_group_label>AGN-242428 Medium Dose</arm_group_label>
    <arm_group_label>AGN-242428 Higher Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as an oral capsule(s) once daily</description>
    <arm_group_label>AGN-242428 Lower Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have a confirmed diagnosis of plaque psoriasis, diagnosed at least 6
             months before study with a PGA score ≥ 3 at screening and baseline.

          -  Severity of disease must be at least moderate, defined as Psoriasis Area and Severity
             Index (PASI) ≥ 12 and % body surface area (BSA) ≥ 10.

          -  Participant is a candidate for phototherapy or systemic therapy for psoriasis.

          -  Body weight of at least 55 kg (121 lbs).

        Exclusion Criteria:

          -  Non-plaque forms of psoriasis (erythrodermic, guttate, pustular) or drug-induced
             psoriasis.

          -  Psoriasis which has not been stable for the 4 weeks prior to screening and which is
             unstable at Study Day 1.

          -  History of Gilbert's, Rotor, or Dubin-Johnson syndromes or any other disorder of
             bilirubin metabolism.

          -  History of active mycobacterium tuberculosis (TB) infection or untreated or
             inadequately treated latent TB.

          -  Positive QuantiFERON test for TB infection at screening.

          -  Had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months prior to
             baseline.

          -  Positive drug and/or alcohol test at screening (with the exception of marijuana).
             Retesting in the case of a positive alcohol test is allowed at the discretion of the
             sponsor.

          -  Current treatment or history of treatment with any anti-TNFα biologic therapy within 3
             months or 5 half-lives of study, and/or all other biologics within 6 months of study
             (Day 1).

          -  Efficacy failure on 2 or more biologic agents for the treatment of psoriasis when the
             failures occurred within 1 year of the initiation of the therapy of the first biologic
             agent.

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin
             (TBL) exceeding 1.5 times the upper limit of normal (ULN) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christy Harutunian</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belleair Research Center</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

